ASKA PHARMACEUTICAL CO., LTD
Get an alert when ASKA PHARMACEUTICAL CO., LTD files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£50M
-22.8% vs 2024
Net assets
£324M
+11.7% vs 2024
Employees
—
Average over period
Profit before tax
£29M
-37.2% vs 2024
Net assets
2-year trend · vs Unclassified median
Accounts
2-year trend · latest reflected 2025-03-31
| Metric | Trend | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Turnover | £294,636,411 | £300,712,645 | |
| Operating profit | £30,474,940 | £24,994,139 | |
| Profit before tax | £46,237,517 | £29,030,897 | |
| Net profit | £35,374,373 | £23,915,795 | |
| Cash | £64,409,958 | £49,711,660 | |
| Total assets less current liabilities | £313,076,094 | £364,081,767 | |
| Net assets | £290,355,854 | £324,417,460 | |
| Equity | £263,162,830 | £281,489,990 | |
| Average employees | — | — | |
| Wages | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating margin | 10.3% | 8.3% | |
| Net margin | 12.0% | 8.0% | |
| Return on capital employed | 9.7% | 6.9% | |
| Gearing (liabilities / total assets) | 31.8% | 31.2% | |
| Current ratio | 2.34x | 2.54x | |
| Interest cover | 162.50x | 104.53x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- Japanese GAAP
- Reporting scope
- Consolidated group
- Auditor
- Seiyo Audit Corporation
- Audit opinion
- Unqualified (clean)
Group structure
- ASKA PHARMACEUTICAL CO., LTD · parent
- Ha Tay Pharmaceutical Joint Stock Company
Significant events
- “Goodwill recognized related to Ha Tay Pharmaceutical Joint Stock Company due to acquisition of additional shares, making it a consolidated subsidiary.”
- “Impairment loss of 12,483 million yen recognized by reducing the carrying amount of goodwill related to Ha Tay Pharmaceutical Joint Stock Company to its recoverable amount.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 1 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| KAIHORI, Yutaka | Director | 2021-08-04 | Dec 1962 | Japanese |
| MARUO, Atsushi | Director | 2021-08-04 | Feb 1959 | Japanese |
| MORI, Maiko | Director | 2022-06-28 | Apr 1964 | Japanese |
| NISHIOKA, Hiroyasu | Director | 2021-08-04 | Dec 1965 | Japanese |
| YAMAGUCHI, Sohta | Director | 2021-08-04 | Dec 1983 | Japanese |
| YAMAGUCHI, Takashi | Director | 2021-08-04 | May 1952 | Japanese |
Show 1 resigned officer
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| KATO, Kazuhiko | Director | 2021-08-04 | 2022-06-28 |
Ownership
Persons with significant control
Filing timeline
Last 15 of 15 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-01-05 | AA | accounts | Accounts with accounts type group | |
| 2025-11-03 | AA01 | accounts | Change account reference date company previous shortened | |
| 2025-10-07 | OSCH02 | other | Change company details overseas company | |
| 2025-03-26 | AA | accounts | Accounts with accounts type full | |
| 2023-12-11 | OSTM03 | officers | Termination person authorised overseas company | |
| 2023-11-29 | AA | accounts | Accounts with accounts type full | |
| 2023-10-25 | OSTM03 | officers | Termination person authorised overseas company | |
| 2023-09-29 | OSAP05 | officers | Appoint person authorised represent overseas company with appointment date | |
| 2023-08-30 | AA | accounts | Accounts with accounts type full | |
| 2023-02-01 | OSCH03 | officers | Change person director overseas company with change date | |
| 2022-12-05 | OSAP01 | officers | Appoint person director overseas company with name appointment date | |
| 2022-12-05 | OSCH03 | officers | Change person director overseas company with change date | |
| 2022-12-05 | OSTM01 | officers | Termination person director overseas company with name termination date | |
| 2021-08-04 | OS-PAR | annual-return | Appointment at registration of person authorised to represent | |
| 2021-08-04 | OSIN01 | incorporation | Register overseas company |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2024 → FY2025 · period ending 2025-03-31 vs 2024-03-31
-
Turnover
+2.1%
£294,636,411 £300,712,645
-
Cash
-22.8%
£64,409,958 £49,711,660
-
Net assets
+11.7%
£290,355,854 £324,417,460
-
Employees
—
Not reported
-
Operating profit
-18%
£30,474,940 £24,994,139
-
Profit before tax
-37.2%
£46,237,517 £29,030,897
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers